INBRAIN Neuroelectronics, a leading brain-computer interface therapeutics (BCI-Tx) company establishing graphene-related neural technologies, has entered a smart partnership with the popular Microsoft company to discover the diversified excellent use of agentic artificial intelligence (AI) sponsored by Microsoft’s data infrastructure and cloud to upgrade future brain-computer interface (BCI) therapeutics and real-time precision neurology.
This collaboration will accelerate Microsoft’s major space of development and growth, such as time-series large language models (LLMs), data analytics potential and Azure AI infrastructure. This will allow INBRAIN’s smart neural platform to learn on a daily basis and feel free to experiment in the area of individual patient signals.
This agentic AI idea, harnessing AI systems providing results based on real-time data, can transition the way neurological disorders are treated and monitored. This will provide closed-loop precision interventions for psychiatric or memory disorders, epilepsy and Parkinson’s disease conditions.
INBRAIN’s neural platform stands on graphene, which is a plain single layer of carbon atoms. The atoms are popular for their precision, biocompatibility and conductivity. By unifying modulation and upgraded decoding with agentic AI, INBRAIN focuses on establishing a new tech unique class of AI-allowed brain-computer interface therapeutics suitable for data-proven, personalised control of neural circuits in real time, unlocking the path to organ therapeutics.
The partnership stands tall on Microsoft’s current investments in responsible data architecture, healthcare AI and cognitive modelling. This represents the joint dedication of both companies towards patient privacy and ethical innovation in neurotechnology establishment.
President of Industry and Enterprise, EMEA at Microsoft, Clare Barclay, said, “This partnership spotlights the next frontier of AI, taking the limelight of tech solutions. INBRAIN’s major operation is an interconnection of AI, bioelectronics and neuroscience, and we are grateful to be able to offer a computational infrastructure and data foundation that will help bolster the mission to enhance neurological health globally.”
Co-Founder and CEO of INBRAIN Neuroelectronics, Carolina Aguilar, said, “Our vision is to generate a personalised, smart and autonomous interface between AI and the nervous system. By partnering with Microsoft, we’re merging our precision graphene neural technology with the powerful and popular AI ecosystems. This collaboration has brought us closer to the next generation brain-computer interfaces, covering advancement in modulation and decoding that deepen the understanding and act responsively to the nervous system in real time, making the body OS.”
Mansi Kadam is a market research writer with over 3 years of experience analyzing trends in the healthcare industry. At Towards Healthcare, she covers innovations in medical sector, sustainability initiatives, and the evolving regulatory landscape.
